| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA719: Secukinumab for treating non-radiographic axial spondyloarthritis |
|
Medicine details |
|
| Medicine name | secukinumab (Cosentyx®) |
| Formulation | 150 mg/ 1 ml solution for injection |
| Reference number | 3305 |
| Indication | Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs) |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/05/2020 |
| NICE guidance | TA719: Secukinumab for treating non-radiographic axial spondyloarthritis |